fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Fluorouracil

All products: general benefit

Efudex · DIN 00330582 · 5% · Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Efudex · DIN 00330582 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2021-06-10 · brand EFUDEX · ATC L01BC02 FLUOROURACIL · form Cream · route Topical · ingredients FLUOROURACIL 5 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Efudex: Formulary list price $1.16 per unit (the source does not state the unit; exact figure $1.1569). What the ministry pays, not the patient.

Ministry pays: $1.1569 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00330582)

Source record
DIN 00330582: Efudex Raw flags: sec3=Y Item: 843600014; group id 862; item number 2084; lccId None; manufacturer id VAL Source form: Cr; strength: 5% Recorded listing: General benefit Source prices (unrounded): $1.1569; ministry $1.1569 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00330582 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00330582
Shortage record checked October 6, 2026
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS EFUDEX is recommended for the topical treatment of premalignant keratoses and superficial basal cell carcinoma. 1.1 Pediatrics (≥ 18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of EFUDEX in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use https://pdf.hres.ca/dpd_pm/00061734.PDF PM date: June 9, 2021 Source product: EFUDEX; DIN 00330582; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.